Ascent Therapeutics gets new funding, new CEO

By Mass High Tech Staff

Ascent Therapeutics adds Tagliamonte, Houston to exec roles [June 3, 2009]

Seahorse Bioscience lands $6M, buys BioProcessors Corp. [March 10, 2009]

Report: Stem cell R&D startup lands $14M round [March 10, 2009]

Proteon pulls in $38M in VC, does Novartis deal worth up to $550M [March 5, 2009]

Ascent Therapeutics Inc., a Cambridge biopharmaceutical firm, has announced a $19 million Series A round of funding from Novartis Option Fund, Healthcare Ventures and TVM Capital. The investment is timed with the appointment of new president and CEO Frederick Jones, as well as the naming of Stephen Hunt as senior vice president of discovery research.

The Ascent board of directors includes Lauren Silverman, managing director of the Novartis Option Fund; Chris Mirabelli, managing director of Healthcare Ventures; and Jens Eckstein, general partner of TVM Capital.

Ascent Therapeutics develops Pepducin drugs, originally invented in the Tufts Medical Center laboratories, to treat inflammation, cancer, CNS disorders and cardiovascular disease. The drugs are designed to target G-protein coupled receptors on the cell membrane.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.